Sarah Milsom

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ.

Sound Pharmaceuticals Inc. manufactures biopharmaceutical products. It focuses on developing drug treatments for sensori-neural hearing loss. The company was founded by Eric Lynch, Joseph Ashley, Glenn H. Kawasaki and Jonathan Kil in 2001 and is headquartered in Seattle, WA.

Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY.

Part of JPMorgan Chase & Co., JPMP Capital LLC is a venture capital firm. The company is based in New York, NY.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY.

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

Carter BloodCare engages in the provision of blood components and transfusion services for North, Central and East Texas. It offers collection, testing, and distribution of blood on a local level. It also provides technical support services and educational programs to employees of area healthcare organizations. The company was founded on January 1, 1998 and is headquartered in Bedford, TX.

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

Imagen Biotech, Inc. develops therapeutics for sight-threatening diseases. The firm specializes in personalized chemotherapy, medicine, high content screening, cell biology and contract research. The company was founded by David R. Guyer and Matthew Feinsod in 2011 and is headquartered in New York, NY.

iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium.

Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee.

Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA.

Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.

Biopharma Co. Ltd. is a South Korean pharmaceutical company that manufactures pharmaceutical ingredients. The company is based in Gunpo, South Korea and was founded in 2019.

Jeito Capital SASU (Jeito Capital) is an Independent Venture Capital firm founded in 2018 by Rafaele Tordjman and headquartered in Paris, France.

Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Invectys, Inc. is a biopharmaceutical company that focuses on developing immunotherapy treatments for cancer. The private company is based in Houston, TX. Invectys was founded in 2010 and Praveen Tyle has been the CEO of the company since 2021.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation.